A carregar...
Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma
The discovery of the BRAF(V600E) mutation led to the development of vemurafenib (PLX4032), a selective BRAF inhibitor specific to the kinase, for the treatment of metastatic melanomas. However, initial success of the drug was dampened by the development of acquired resistance. Melanoma was shown to...
Na minha lista:
| Publicado no: | Int J Mol Sci |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5536016/ https://ncbi.nlm.nih.gov/pubmed/28708099 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms18071527 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|